TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04708886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Year 1 study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Year 2 study drug
Study: NCT06143371

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CAN10 - Placebo
Description: Single dose intravenous or Multiple doses subcutaneously
Study: NCT06124157

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and CSF sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and CSF sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Receive IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calaspargase Pegol
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Receive IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Receive IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Receive IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Receive PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Receive PO or NG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Receive IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Receive IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Receive PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Receive PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Receive PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Receive PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Receive IT or IV
Study: NCT05655247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split-thickness non-advanced tunnel (Zabalegui et al. 1999)
Description: A split-thickness non-advanced tunnel will be performed according to Zabalegui et al. (1999).
Study: NCT05655247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-thickness coronally-advanced tunnel (Aroca et al. 2010)
Description: A full-thickness coronally-advanced tunnel (Modified Coronally Advanced Tunnel - MCAT) will be performed according to Aroca et al. (2010).
Study: NCT05209581

Intervention type: DIAGNOSTIC_TEST
Intervention: Distance Visual Acuity Examination
Description: Best spectacle-corrected distance visual acuity of refugees/immigrants will be examined via a web-based digital visual acuity chart
Study: NCT06521944

Intervention type: BIOLOGICAL
Intervention: RSV Vaccine
Description: RSV Vaccine approved for administration to pregnant individuals between 32 weeks, 0 days and 36 weeks, 6 days of gestation

Intervention type: OTHER
Intervention: Non-exposure to RSV Vaccine
Description: Pregnant individuals who are not exposed to the RSV vaccine
Study: NCT06124157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Receive IT or IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Receive IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Receive PO
Study: NCT06322394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose BXOS110
Description: 3.0 mg/kg, maximum dose not exceeding 300 mg，Participants received one administration by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose BXOS110
Description: 2.0 mg/kg, maximum dose not exceeding 200 mg，Participants received one administration by intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Does not contain any test drug active ingredients，Participants received one administration by intravenous infusion.
Study: NCT04696107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducative intervention
Description: This workshop is centred in psychoeducational and training action in emotional self-regulation in a group modality and participatory character, aimed at patients with mCNCP to acquire basic knowledge in:~* Neurology and psychoneuroimmunology.~* The role of beliefs in our manifestation of the disease.~* Body language and modulation of pain perception.~* Relaxation body-mind techniques.~* Creative visualization for pain management.~* Mirror feed-back.~The workshop will take place at the Hospital San Juan de Dios del Aljarafe, in four weeks, once a week, three hours each. Until now, the attendance was 24 patients per workshop. After the pandemic, we will reduce to 15 to increase safety distance. We will also conduct a telephone survey of each patient on symptoms of Covid infection in the 24 hours prior to the workshop.
Study: NCT06045819

Intervention type: BIOLOGICAL
Intervention: Blood sampling for venetoclax drug dosage (venous puncture)
Description: 8 blood samples for venetoclax and azole antifungal drugs identification and dosage will be taken by venous and capillary punctures throughout management of patients

Intervention type: BIOLOGICAL
Intervention: Blood sampling for venetoclax drug dosage (venous puncture)
Description: 8 blood samples for venetoclax and azole antifungal drugs identification and dosage will be taken by venous and capillary punctures throughout management of patients
Study: NCT06456437

Intervention type: DEVICE
Intervention: Post-conditioning Balloon dilation and contraction
Description: The balloon was filled at a pressure of no more than 4 atm at the original occlusion of the vessel to block blood flow for 2 minutes (confirmed by angiography), and then contracted to reperfuse the blood flow for 2 minutes, and the above steps were repeated 4 times to complete the in situ ischaemic post-acclimatisation intervention.
Study: NCT05320848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation
Description: Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.
Study: NCT04866849

Intervention type: OTHER
Intervention: examination
Description: The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes.

Intervention type: OTHER
Intervention: examination
Description: The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes.
Study: NCT05460559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A (p-PCNL) procedure
Description: In lithotomy position, ureteric catheter will be inserted allowing injection of contrast to obtain a pyelogram. Shifting the patients in prone position will be done. Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B (s-ECIRS) procedure
Description: The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
Study: NCT05417360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Akkermansia muciniphila
Description: During the weight management period (weeks 8 to 32), the pasteurized A. muciniphila product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks) capsules. It appears as a white homogenous powder.~.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the weight management period (weeks 8 to 32), the placebo product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks). It appears as a white homogenous powder.
Study: NCT06375252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Central Jugular Vein Catheter Lumen Holder Apparatus
Description: Participants will experience the central jugular vein catheter lumen holder apparatus, perform walking, sitting, supine, right and left side lying activities and fill out the evaluation forms prepared by the researcher. They will then experience the same activities without the apparatus.
Study: NCT06124157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Receive PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Receive PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Receive PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Receive PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Receive IV
Study: NCT04641819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangzheng Compound Mixture
Description: At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance.~Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Treatment
Description: Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.
Study: NCT05833217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose Tissue Biopsy
Description: After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Participants will have a local anesthetic prior to the procedure. The needle fat biopsy will be repeated at quarterly intervals for one year (every 3 months). We will also draw 1 10mL tube of blood at each biopsy for measurement of inflammatory cytokines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose Tissue Biopsy
Description: After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Participants will have a local anesthetic prior to the procedure. The needle fat biopsy will be repeated at quarterly intervals for one year (every 3 months). We will also draw 1 10mL tube of blood at each biopsy for measurement of inflammatory cytokines.
Study: NCT04871542

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05833217

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Steady State Plasma Glucose (SSPG) Test
Description: An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if participants are insulin sensitive or insulin resistant. This test is approximately 5-6 hours in length. Participants will be asked to fast for 12 hours. The insulin sensitivity test is designed to measure how well your cells remove glucose from your blood in response to insulin. During this test participants will have two small catheters (tubing) placed in their veins (I.V. lines). The total amount of blood that will be drawn during this test will be 140 mL of blood (approximately 9.5 tablespoons). Insulin is a natural hormone, and octreotide (a synthetic hormone) is a drug that temporarily blocks the secretion of insulin from your pancreas. A member of the research team is present and monitoring the results along with the nursing staff.
Study: NCT06283173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColActive Plus Collagen Matrix Dressing
Description: Induction phase: Test article applied with Hill Top chamber every 48+ hours over 3 weeks. Rest phase: 10-day rest period with no application.~Challenge phase: Test article applied for 48 hours and evaluated through 48 hours post removal.~The positive control is evaluated at Induction 1 only. The negative control is applied following the same schedule as the test article.
Study: NCT05312242

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) MMS
Description: Introduction of UNIMMAP MMS along with novel counseling strategies to increase acceptability and adherence to prenatal supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) MMS
Description: Introduction of UNIMMAP MMS along with novel counseling strategies to increase acceptability and adherence to prenatal supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Folic Acid Supplement
Description: Standard of Care Intervention
Study: NCT06387459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fabric-Type Knee Extensor Muscle-Mimicking Orthosis
Description: The intervention device is a fabric-based orthosis incorporating shape-memory alloy springs designed to mimic the action of knee extensor muscles. The primary function of this orthosis is to provide supplementary support to the knee joint during walking, aiming to stabilize the gait of elderly individuals affected by muscle weakness or degenerative joint conditions. Material: The orthosis is made from a lightweight, flexible fabric that allows for breathability and comfort during extended wear. Mechanism: Embedded within the fabric are shape- memory alloy springs that function similarly to biological muscles.
Study: NCT06063759

Intervention type: DEVICE
Group type: OTHER
Intervention: VitalDetect
Description: measurement of microcirculating blood flow, SpO2 (mmHg or %), heart rate (beats/min)
Study: NCT05850247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714 PET
Description: To assess the association between plasma ficolin-2 levels and plaque and brain inflammation assessed by \[18F\]DPA-714 PET/MRI in patients managed for transient ischaemic attack or ischaemic stroke related to carotid stenosis.
Study: NCT03995160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of closed suction drainage following total knee arthroplasty
Description: Use of closed suction drainage following total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abstain of using a closed suction drainage
Description: Abstain of using a closed suction drainage following total knee arthroplasty
Study: NCT05117814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: as long as 24 months or consolidated with ASCT or WBRT after achieving PR or CR
Study: NCT04699344

Intervention type: DIAGNOSTIC_TEST
Intervention: The level of CNV
Description: The extracted DNA from morning urine will be analyzed by PROUD to determine the level of CNV.

Intervention type: DIAGNOSTIC_TEST
Intervention: The level of CNV
Description: The extracted DNA from morning urine will be analyzed by PROUD to determine the level of CNV.
Study: NCT05816824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom monitoring software via visual feedback
Description: With PhysioAnalyst software, individuals are evaluated using clinical tools (questionnaire, scale). These evaluations provide visual feedback to individuals in the form of tables and graphs. In this way, patients can observe the changes in their clinical status.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom monitoring software via visual feedback
Description: With PhysioAnalyst software, individuals are evaluated using clinical tools (questionnaire, scale). These evaluations provide visual feedback to individuals in the form of tables and graphs. In this way, patients can observe the changes in their clinical status.
Study: NCT06006871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game
Description: Patients are pharmacologically stable and receive a cognitive intervention with our videogame twice a week in the hospital (10 sessions) and twice a week in their home with a computer video game (other 10 sessions).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment for ADHD
Description: All patients continue with their stable pharmacological treatment and do not receive any additional cognitive intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual treatment for ADHD
Description: All patients continue with their stable pharmacological treatment and do not receive any additional cognitive intervention.
Study: NCT05465525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block Type III
Description: Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Block
Description: The patients will receive general anesthesia.
Study: NCT06360419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Description: Solriamfetol tablets, taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken once daily
Study: NCT04841954

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: hemp prick-test
Description: hemp seed and flower prick-test
Study: NCT06110403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIXEO AEROSPHERE
Description: BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days.